Using lower price generic medicines for chronic diseases provides efficacy similar to branded medicines. However, previous studies showed that disadvantaged people, who may particularly benefit from cost savings, have low trust on generics and showed increased reluctance to switch to generics. The rural areas include areas of high poverty and minority communities whose members are at high risk for poor health outcomes. However, whether such beliefs exist in these communities has not been reported. We sought to obtain qualitative insights about awareness and usage of generic medication among the people in urban and rural areas of Kakinada city. This survey showed that there is a gap in consumers' awareness and availability of generic medicines in urban and rural areas of Kakinada. The findings of the study suggest that awareness needs to be spread among the customers about generic medicines. Besides, it is an emerging business opportunity for local medical retailers.

1. Abbott, F.M. (2013, April 04). Inside views: The judgment in Novartis v. India: What the Supreme Court of India said. Intellectual Property Watch. Retrieved from <a href=http://www.ip-watch.org/2013/04/04/the-judgment-in-novartis-v-india-what-the-supreme-court-of-india-said/ target="_blank">http://www.ip-watch.org/2013/04/04/the-judgment-in-novartis-v-india-what-the-supreme-court-of-india-said/</a>
2. Aiyar, S.A. (2013). West should learn from India's high patent standards. Retrieved from <a href=http://www.scribd.com/doc/153150555/Swaminathan-Aiyar-Article-on-7th-April-West-Should-Learn-From-India target="_blank">http://www.scribd.com/doc/153150555/Swaminathan-Aiyar-Article-on-7th-April-West-Should-Learn-From-India</a>
3. Babar, Z.U., Stewart, J., Reddy, S., Alzaher, W., Vareed, P., Yacoub, N. .... & Rew, A. (2010). An evaluation of consumers' knowledge, perceptions and attitudes regarding generic medicines in Auckland. Pharm World Science Journal, 32(4), 440-448. DOI: 10.1007/s11096-010-9402-0.
4. Banka, N. (2013). The critical analysis of Novartis v. Cipla case verdict by Supreme Court [web log post]. Retrieved from <a href=http://legalconnectindia.blogspot.in/2013/04/the-critical-analysis-of-novartis-v.html target="_blank">http://legalconnectindia.blogspot.in/2013/04/the-critical-analysis-of-novartis-v.html</a>
5. Basheer, S. (2005). India's tryst with TRIPS: The Patents (Amendment) Act, 2005. The Indian Journal of Law and Technology, 1(1), 15-46. Retrieved from <a href=http://www1.nls.ac.in/ojs-2.2.3/index.php/IJLT/article/viewFile/7/5 target="_blank">http://www1.nls.ac.in/ojs-2.2.3/index.php/IJLT/article/viewFile/7/5</a>
6. Bennett, D. E., Bertagnolio, S., Sutherland, D., & Gilks, C.F. (2008). The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy, 13(2), 1-13. Retrieved from <a href=http://www.who.int/hiv/drugresistance/WHO_HIVDR_strategy.pdf target="_blank">http://www.who.int/hiv/drugresistance/WHO_HIVDR_strategy.pdf</a>
7. Gaither, C.A., Kirking, D.M., Ascione, F.J., & Welage, L.S. (2001). Consumers' views on generic medications. Journal of American Pharmacists Association, 41 (5), 729-736.
8. Grover, A. (2013, April 02). Novartis case: Supreme Court's historic decision on Section 3(d). The Times of India. Retrieved from <a href=http://articles.timesofindia.indiatimes.com/2013-04-02/india/38217259_1_therapeutic-efficacy-chennai-patent-office-patent-oppositions target="_blank">http://articles.timesofindia.indiatimes.com/2013-04-02/india/38217259_1_therapeutic-efficacy-chennai-patent-office-patent-oppositions</a>
9. Generic drug. (n.d.). In Wikipedia. Retrieved August 16, 2013, from <a href=http://en.wikipedia.org/wiki/Generic_drug target="_blank">http://en.wikipedia.org/wiki/Generic_drug</a>
10. Gill, L., Helkkula, A., Cobelli, N., & White, L. (2010). How do customers and pharmacists experience generic substitution? International Journal of Prognostics and Health Management, 4 (4), 375-395.
11. Hannon, E. (2012, August 21). How an Indian patent case could shape the future of generic drugs. Time World. Retrieved from <a href=http://world.time.com/2012/08/21/how-an-indian-patent-case-could-shape-the-future-of-generic-drugs/#ixzz2E3oygauR target="_blank">http://world.time.com/2012/08/21/how-an-indian-patent-case-could-shape-the-future-of-generic-drugs/#ixzz2E3oygauR</a>
12. Haskins, L.S., Tomaszewski, K.J., & Crawford, P. (2005). Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy& Behaviour, 7 (1), 98-105.
13. Himmel, W., Simmenroth Nayda, A., Niebling, W., Ledig, T., Jansen, R.D, Kochen, M.M., Gleiter, C.H., Hummers-Pradier, E. (2005).What do primary care patients think about generic drugs? International Journal of Clinical Pharmacology Therapeutics, 43 (10), 472-479.
14. Kakinada. (n.d.). In Wikipedia. Retrieved August 16, 2013, from <a href=http://en.wikipedia.org/wiki/Kakinada target="_blank">http://en.wikipedia.org/wiki/Kakinada</a>
15. Kjoenniksen I., Lindbaek M., & Granas, A. G. (2006). Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharmacy World and Science, 28 (5), 284-289.
16. Love, J. (2011). The production of generic drugs in India. BMJ, 342. DOI: <a href=http://dx.doi.org/10.1136/bmj target="_blank">http://dx.doi.org/10.1136/bmj</a>
17. Mohanta, G.P., Jana, U., & Manna, P.K. (2012, December 19). Promoting generic medicines. Pharmabiz.com. Retrieved from <a href=http://www.pharmabiz.com/ArticleDetails.aspx?aid=72777&sid=9 target="_blank">http://www.pharmabiz.com/ArticleDetails.aspx?aid=72777&sid=9</a>
18. Nair, G.G. (2008). Impact of TRIPS on Indian pharmaceutical industry. Journal of Intellectual Property Rights, 13 (9), 432-441.
19. Novartis v. Union of India & Others. (n.d.). In Wikipedia. Retrieved August 16, 2013, from <a href=http://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others target="_blank">http://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others</a>
20. Palagyi M., & Lassanova M. (2008). Patients attitudes towards experience with use of generics in Slovakia, performance of generic substitution. Bratisl Lek Listy, 109 (7), 324-328.
21. Roman,B. (2009). Patients' attitudes towards generic substitution of oral atypical antipsychotics: A questionnaire-based survey in a hypothetical pharmacy setting. CNS Drugs, 23 (8), 693-701. DOI: 10.2165/00023210-200923080-00006
22. Shrank, W.H., Cox, E.R., Fischer, M.A., Mehta, J., & Choudhry, N.K. (2009). Patients' perceptions of generic medications. Health Aff (Millwood), 28 (2), 546-556. DOI: 10.1377/hlthaff.28.2.546.
23. Supreme Court's decision on Novartis to benefit poor patients: Pharma companies. (2013, April 1). The Economic Times. Retrieved from <a href=http://articles.economictimes.indiatimes.com/2013-04-01/news/38189629_1_poor-patients-judgement-glivec target="_blank">http://articles.economictimes.indiatimes.com/2013-04-01/news/38189629_1_poor-patients-judgement-glivec</a>
24. Supreme Court to pass landmark judgement on Novartis pharma patents case today. (2013, April 01). India Today. Retrieved from <a href=http://indiatoday.intoday.in/story/novartis-patent-case-supreme-court-judgement/1/260082.html target="_blank">http://indiatoday.intoday.in/story/novartis-patent-case-supreme-court-judgement/1/260082.html</a>
25. Vallès J. A. et al. (2003). A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy, 65 (3), 269-275.